why choose us

First received: June 05, 2023

Clinical Trial: First-in-human, Single Ascending Dose Study of CEL383 in Healthy Adult Subjects

Study Status: Completed

Recruit Status: RECRUITING

Condition: Healthy

Study Type: INTERVENTIONAL


Official Title: A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CEL383 When Administered Intravenously to Health

Brief Summary: This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of CEL383 in healthy volunteers.

Read more